We are live on ! Find out more
QDEL icon

QuidelOrtho

15.32 USD
+0.41
2.75%
At close Updated Aug 27, 4:00 PM EDT
1 day
2.75%
5 days
2.41%
1 month
-8.97%
3 months
24.25%
6 months
-32.63%
Year to date
-46.77%
1 year
-44.83%
5 years
-88%
10 years
-29.5%
 

About: QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

Employees: 6,500

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 29.2%
Neutral 58.3%
Negative 12.5%
Neutral
PRNewsWire
13 hours ago
Faster Answers, Better Decisions: ADLM 2026 Highlights
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.
Faster Answers, Better Decisions: ADLM 2026 Highlights
Negative
Zacks Investment Research
10 days ago
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
Neutral
Zacks Investment Research
10 days ago
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
Positive
Zacks Investment Research
10 days ago
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
Positive
Zacks Investment Research
17 days ago
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
Neutral
Seeking Alpha
20 days ago
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
Negative
MarketBeat
20 days ago
QuidelOrtho Q2 Earnings Call Highlights
QuidelOrtho NASDAQ: QDEL reported second-quarter revenue growth despite continued pressure from China and a softer respiratory testing environment, while lowering its full-year outlook and withdrawing free cash flow guidance.
QuidelOrtho Q2 Earnings Call Highlights
Positive
Zacks Investment Research
21 days ago
QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates
QuidelOrtho (QDEL) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.12 per share a year ago.
QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates
Neutral
PRNewsWire
21 days ago
QuidelOrtho Reports Second Quarter 2026 Financial Results
― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ―  ― Excluding China, total revenue grew 6% both as reported and in constant currency ― ― Company updates full-year 2026 financial guidance ― SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the second quarter ended June 28, 2026. Key Second Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $631 million, an increase of 3% as reported and 2% in constant currency.
QuidelOrtho Reports Second Quarter 2026 Financial Results
Neutral
Zacks Investment Research
22 days ago
Implied Volatility Surging for QuidelOrtho Stock Options
Investors need to pay close attention to QDEL stock based on the movements in the options market lately.
Implied Volatility Surging for QuidelOrtho Stock Options
Price charts implemented using Lightweight Charts™